Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
– Results from the first patient cohort (N=5) of an open-label proof of concept academic study with low-dose IL-2 and […]